IVDR: Analysis of the Social, Economic, and Practical Consequences of the Application of an Ordinance of the In Vitro Diagnostic Ordinance in Switzerland
- PMID: 37761277
- PMCID: PMC10529212
- DOI: 10.3390/diagnostics13182910
IVDR: Analysis of the Social, Economic, and Practical Consequences of the Application of an Ordinance of the In Vitro Diagnostic Ordinance in Switzerland
Abstract
IVDR regulation represents a major challenge for diagnostic microbiology laboratories. IVDR complicates a broad range of aspects and poses a risk given the high diversity of pathogens (including rare but highly virulent microbes) and the large variety of samples submitted for analysis. The regular emergence of new pathogens (including Echovirus E-11, Adenovirus 41, Monkeypox virus, Alongshan virus, and Enterovirus D68, as recent examples in Europe in the post SARS-CoV-2 era) is another factor that makes IVDR regulation risky, because its detrimental effect on production of in-house tests will negatively impact knowledge and expertise in the development of new diagnostic tests. Moreover, such regulations negatively impact the availability of diagnostic tests, especially for neglected pathogens, and has a detrimental effect on the overall costs of the tests. The increased regulatory burden of IVDR may thereby pose an important risk for public health. Taken together, it will have a negative impact on the financial balance of diagnostic microbiology laboratories (especially small ones). The already-high standards of quality management of all ISO-accredited and Swissmedic-authorized laboratories render IVDR law of little value, at least in Switzerland, while tremendously increasing the regulatory burden and associated costs. Eventually, patients will need to pay for diagnostic assays outside of the framework of their insurance in order to obtain a proper diagnostic assessment, which may result in social inequity. Thus, based on the risk assessment outlined above, the coordinated commission for clinical microbiology proposes adjusting the IvDO ordinance by (i) introducing an obligation to be ISO 15189 accredited and (ii) not implementing the IvDO 2028 milestone.
Keywords: IVDR; consequences; microbiology; risks.
Conflict of interest statement
All authors are lab managers active in Switzerland and are impacted by the IvDO. G Greub has a research agreement with Becton-Dickinson on their BD Kiestra lab automated system and is medical advisor of Resistell, a start-up developing a new device for testing antibiotic susceptibility of bacteria. G Greub is also co-director of JeuPRO, a game company distributing games on microbes. A Egli is a medical advisor of two start-up companies, Sefunda and PhAST, both of which are developing rapid pathogen detection assays. However, no authors have a direct conflict of interest with the present position paper.
Figures
Similar articles
-
ISO 15189 is a sufficient instrument to guarantee high-quality manufacture of laboratory developed tests for in-house-use conform requirements of the European In-Vitro-Diagnostics Regulation.Clin Chem Lab Med. 2023 Jan 31;61(4):608-626. doi: 10.1515/cclm-2023-0045. Print 2023 Mar 28. Clin Chem Lab Med. 2023. PMID: 36716120 Review.
-
[Impact of the novel in vitro diagnostic regulation (IVDR) of the European Union on pathology laboratories. What's important?].Pathologe. 2020 Dec;41(Suppl 2):129-133. doi: 10.1007/s00292-020-00867-9. Pathologe. 2020. PMID: 33263810 Review. German.
-
Implementing Regulation (EU) 2017/746 of 5 April 2017 on In vitro Diagnostic Medical Devices (IVDR) in Medical Laboratories, especially in Ophthalmopathology.Klin Monbl Augenheilkd. 2022 Jul;239(7):905-912. doi: 10.1055/a-1863-9331. Epub 2022 May 30. Klin Monbl Augenheilkd. 2022. PMID: 35636459 English, German.
-
Advisory opinion of the AWMF Ad hoc Commission In-vitro Diagnostic Medical Devices regarding in-vitro diagnostic medical devices manufactured and used only within health institutions established in the Union according to Regulation (EU) 2017/746 (IVDR).Ger Med Sci. 2021 Jun 1;19:Doc08. doi: 10.3205/000295. eCollection 2021. Ger Med Sci. 2021. PMID: 34194291 Free PMC article.
-
Laboratory-Developed Tests: Design of a Regulatory Strategy in Compliance with the International State-of-the-Art and the Regulation (EU) 2017/746 (EU IVDR [In Vitro Diagnostic Medical Device Regulation]).Ther Innov Regul Sci. 2022 Jan;56(1):47-64. doi: 10.1007/s43441-021-00323-7. Epub 2021 Jul 21. Ther Innov Regul Sci. 2022. PMID: 34291407 Free PMC article. Review.
Cited by
-
A Comparative Analysis of Molecular Biological Methods for the Detection of SARS-CoV-2 and Testing the In Vitro Infectivity of the Virus.Microorganisms. 2024 Jan 17;12(1):180. doi: 10.3390/microorganisms12010180. Microorganisms. 2024. PMID: 38258006 Free PMC article.
References
-
- European Union In vitro Diagnostic regulation. 2017. [(accessed on 1 July 2023)]. Available online: https://eur-lex.europa.eu/eli/reg/2017/746/oj.
-
- The Swiss Federal Council Ordinance on In Vitro Diagnostic Medical Devices (IvDO) 2022. [(accessed on 1 July 2023)]. Available online: https://www.fedlex.admin.ch/filestore/fedlex.data.admin.ch/eli/cc/2022/2....
-
- Bank P.C.D., Jacobs L.H.J., van den Berg S.A.A., van Deutekom H.W.M., Hamann D., Molenkamp R., Ruivenkamp C.A.L., Swen J.J., Tops B.B.J., Wamelink M.M.C., et al. The end of the laboratory developed test as we know it? Recommendations from a national multidisciplinary taskforce of laboratory specialists on the interpretation of the IVDR and its complications. Clin. Chem. Lab. Med. 2020;59:491–497. doi: 10.1515/cclm-2020-1384. - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous